Highly clonal regulatory T-cell population in follicular lymphoma - inverse correlation with the diversity of CD8+ T cells

OncoImmunology

Volumn 4, Issue 5, 2015, Pages

  Liu, Xiao ^a   Venkataraman, Girish ^a   Lin, Jiaying ^a   Kiyotani, Kazuma ^a   Smith, Sonali ^a   Montoya, Magdeline ^a   Nakamura, Yusuke ^a   Kline, Justin ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Follicular lymphoma (FL); Next generation sequencing (NGS); T cell receptor (TCR); Tumor microenvironment

Indexed keywords

CD20 ANTIGEN; CD45 ANTIGEN; PROTEIN BCL 2; PROTEIN BCL 6; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ADULT; ARTICLE; BINDING AFFINITY; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; FOLLICULAR LYMPHOMA; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MATHEMATICAL PARAMETERS; MIDDLE AGED; MISSENSE MUTATION; NEXT GENERATION SEQUENCING; OUTCOME ASSESSMENT; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE CHARACTERIZATION; TUMOR MICROENVIRONMENT;

EID: 84944452907     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2014.1002728     Document Type: Article

References (37)

1. Swenson WT, Wooldridge JE, Lynch CF, Forman-Hoffman VL, Chrischilles E, Link BK. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 2005; 23:5019-26; PMID:15983392; http://dx.doi.org/10.1200/JCO. 2005.04.503
2. Al-Tourah AJ, Gill KK, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, Sehn LH, Shenkier TN, Gascoyne RD, Connors JM. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol 2008; 26:5165-9; PMID:18838711; http://dx.doi.org/10.1200/ JCO.2008.16.0283
3. Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, Au WY, Bellei M, Brice P, Caballero D, et al. Follicular Lymphoma International Prognostic Index. Blood 2004; 104:1258-65; PMID:15126323; http://dx.doi.org/10.1182/blood-2003-12-4434
4. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM, et al. Prediction of survival in follicular lymphoma based on molecular features of tumorinfiltrating immune cells. N Engl J Med 2004; 351:2159-69; PMID:15548776; http://dx.doi.org/ 10.1056/NEJMoa041869
5. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984; 311:1471-5; PMID:6548796; http://dx.doi.org/10.1056/NEJM198412063112303
6. Levy R, Ganjoo KN, Leonard JP, Vose JM, Flinn IW, Ambinder RF, Connors JM, Berinstein NL, Belch AR, Bartlett NL, et al. Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. J Clin Oncol 2014; 32:1797-803; PMID:24799467; http://dx.doi.org/10.1200/JCO.2012.43.9273
7. Lee AM, Clear AJ, Calaminici M, Davies AJ, Jordan S, MacDougall F, Matthews J, Norton AJ, Gribben JG, Lister TA, Goff LK. Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol 2006; 24:5052-9; published online EpubNov 1 (10.1200/ JCO.2006.06.4642); PMID:17033038; http://dx.doi. org/10.1200/JCO.2006.06.4642
8. Alvaro T, Lejeune M, Salvado MT, Lopez C, Jaen J, Bosch R, Pons LE. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol 2006; 24:5350-7; PMID:17135637; http://dx.doi.org/10.1200/JCO.2006.06.4766
9. Farinha P, Masoudi H, Skinnider BF, Shumansky K, Spinelli JJ, Gill K, Klasa R, Voss N, Connors JM, Gascoyne RD. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005; 106:2169-74; PMID:15933054; http://dx.doi.org/10.1182/blood-2005-04-1565
10. Glas AM, Knoops L, Delahaye L, Kersten MJ, Kibbelaar RE, Wessels LA, van Laar R, van Krieken JH, Baars JW, Raemaekers J, et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 2007; 25:390-8; PMID:17200149; http://dx.doi.org/10.1200/ JCO.2006.06.1648
11. Farinha P, Al-Tourah A, Gill K, Klasa R, Connors JM, Gascoyne RD. The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. Blood 2010; 115:289-95; PMID:19901260; http://dx.doi.org/10.1182/blood-2009-07-235598
12. Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, Wunderlich JR, Mixon A, Farid S, Dudley ME, et al. PD-1 identifies the patient-specific CD8(+) tumorreactive repertoire infiltrating human tumors. J Clin Invest 2014; 124:2246-59; PMID:24667641; http:// dx.doi.org/10.1172/JCI73639
13. Fang H, Yamaguchi R, Liu X, Daigo Y, Yew PY, Tanikawa C, Matsuda K, Imoto S, Miyano S, Nakamura Y. Quantitative T cell repertoire analysis by deep cDNA sequencing of T cell receptor α and β chains using next-generation sequencing (NGS). Oncoimmunology 2014; 3(12): e968467; http://dx.doi.org/10.4161/ 21624011.2014.968467
14. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998; 58:3491-4; PMID:9721846
15. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353:2654-66; PMID:16371631; http://dx. doi.org/10.1056/NEJMoa051424
16. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Nat Acad Sci USA 2005; 102:18538-43; PMID:16344461; http://dx.doi.org/10.1073/ pnas.0509182102
17. Clemente CG, Mihm MC, Jr., Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996; 77:1303-10; PMID:8608507; http://dx.doi.org/10.1002/(SICI)1097-0142(19960401)77:7%3c1303::AID-CNCR12%3e3.0. CO;2-5
18. van Houdt IS, Sluijter BJ, Moesbergen LM, Vos WM, de Gruijl TD, Molenkamp BG, van den Eertwegh AJ, Hooijberg E, van Leeuwen PA, Meijer CJ, et al. Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression. Intl J Cancer 2008; 123:609-15; http://dx. doi.org/10.1002/ijc.23543
19. Man K, Miasari M, Shi W, Xin A, Henstridge DC, Preston S, Pellegrini M, Belz GT, Smyth GK, Febbraio MA, et al. The transcription factor IRF4 is essential for TCR affinity-mediated metabolic programming and clonal expansion of T cells. Nature Immunol 2013; 14:1155-65; http://dx.doi.org/10.1038/ni.2710
20. Turner SJ, Doherty PC, McCluskey J, Rossjohn J. Structural determinants of T-cell receptor bias in immunity. Nature Rev Immunol 2006; 6:883-94; http://dx.doi.org/10.1038/nri1977
21. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299:1057-61; PMID:12522256; http:// dx.doi.org/10.1126/science.1079490
22. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nature Immunol 2005; 6:1142-51; http://dx.doi.org/10.1038/ni1263
23. Fontenot JD, Rudensky AY. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nature Immunol 2005; 6:331-7; http://dx.doi.org/10.1038/ ni1179
24. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nature Rev Immunol 2006; 6:295-307; http://dx.doi.org/10.1038/nri1806
25. Kline J, Brown IE, Zha YY, Blank C, Strickler J, Wouters H, Zhang L, Gajewski TF. Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. Clinical Can Res 2008; 14:3156-67; http://dx.doi.org/10.1158/1078-0432.CCR-07-4696
26. Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001; 194:823-32; PMID:11560997; http://dx. doi.org/10.1084/jem.194.6.823
27. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, Zhang A, Dahm P, Chao N, Gilboa E, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005; 115:3623-33; PMID:16308572; http://dx.doi.org/10.1172/ JCI25947
28. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999; 59:3128-33; PMID:10397255
29. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Med 2004; 10:942-9; PMID:15322536; http://dx.doi.org/ 10.1038/nm1093
30. deLeeuw RJ, Kost SE, Kakal JA, Nelson BH. The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Can Res 2012; 18:3022-9; http://dx.doi.org/10.1158/ 1078-0432.CCR-11-3216
31. Carreras J, Lopez-Guillermo A, Fox BC, Colomo L, Martinez A, Roncador G, Montserrat E, Campo E, Banham AH. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006; 108:2957-64; PMID:16825494; http:// dx.doi.org/10.1182/blood-2006-04-018218
32. Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA, Dirnhofer S. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 2008; 93:193-200; PMID:18223287; http://dx.doi.org/10.3324/ haematol.11702
33. Shevach EM. Mechanisms of foxp3+ T regulatory cellmediated suppression. Immunity 2009; 30:636-45; PMID:19464986; http://dx.doi.org/10.1016/j. immuni.2009.04.010
34. Laurent C, Muller S, Do C, Al-Saati T, Allart S, Larocca LM, Hohaus S, Duchez S, Quillet-Mary A, Laurent G, et al. Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: a 3-D tissue-imaging study. Blood 2011; 118:5371-9; PMID:21856865; http://dx.doi.org/ 10.1182/blood-2011-04-345777
35. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Ann Rev Immunol 2004; 22:329-60; http://dx.doi.org/10.1146/annurev. immunol.22.012703.104803
36. Kridel R, Sehn LH, Gascoyne RD. Pathogenesis of follicular lymphoma. J Clin Invest 2012; 122:3424-31; PMID:23023713; http://dx.doi.org/10.1172/ JCI63186
37. Gribben JG. Immune responses and outcome in follicular lymphoma. J Clin Oncol 2014; 32:1757-9; PMID:24799493; http://dx.doi.org/10.1200/ JCO.2013.53.8439